| Date:4/26/2021 |
|--|
| Your Name:Lael Yonker |
| Manuscript Title: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrier leading to SARS-CoV-2 antigenemia |
| Manuscript number (if known): 149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | xNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | xNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | xNone | |
| | | | |
| | | | |
| 4 | Consulting fees | xNone | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | xNone |
|----|--|-------|
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

| Date:4/26/2021 |
|--|
| Your Name:Tal Gilboa |
| Manuscript Title: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrier leading to SARS-CoV-2 antigenemia |
| Manuscript number (if known): 149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Time frame: Since the initialxNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x_None | |
|----|--|--------|--|
| 6 | Payment for expert testimony | xNone | |
| 7 | Support for attending meetings and/or travel | xNone | |
| 8 | Patents planned, issued or pending | xNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone | |
| 11 | Stock or stock options | xNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone | |
| 13 | Other financial or non- financial interests | xNone | |

| Date:4/26/2021 | |
|---|--|
| Your Name:Alana Ogata | |
| Manuscript Title: Multisystem Inflammatory S | yndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrier leading to SARS-CoV-2 antigenen | ia |
| Manuscript number (if known): 149633-JCI | -CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date: | 4/26/2021 |
|-----------------|--|
| Your Name: | _Yasmeen Senussi |
| Manuscript Titl | le: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | r leading to SARS-CoV-2 antigenemia |
| Manuscript nui | mber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date: | _4/26/2021 |
|-----------------------|--|
| Your Name: | Roey Lazarovits |
| Manuscript Tit | le: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | mber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date: | _4/26/2021 |
|-----------------------|---|
| Your Name: | Brittany P. Boribong |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | mber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date: | _4/26/2021 | |
|---|--|--|
| Your Name: | Yannic C. Bartsch | |
| Manuscript Tit | le: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut | |
| mucosal barrier leading to SARS-CoV-2 antigenemia | | |
| Manuscript nu | mber (if known <u>):149633-JCI-CMED-RV-2</u> | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date: | _4/26/2021 |
|-----------------------|---|
| Your Name: | Maggie Loiselle |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | Imber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date:4/26/2021 | | | | |
|---|--|--|--|--|
| Your Name: Magali Noval Rivas | | | | |
| Manuscript Title: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> | | | | |
| mucosal barrier leading to SARS-CoV-2 antigenemia | | | | |
| Manuscript number (if known): <u>149633-JCI-CMED-RV-2</u> | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|--|--------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, | x_None | |
| | speakers bureaus, manuscript writing or educational events | | |
| 6 | Payment for expert testimony | xNone | |
| 7 | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or pending | xNone | |
| | pending | | |
| 9 | Participation on a Data | xNone | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock options | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | xNone | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- financial interests | xNone | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Rebecca Porritt |
| Manuscript Tit | le: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | mber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Rosiane Lima |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Jameson Davis |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Eva Farkas |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|---|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 Participation on a Data Safety Monitoring Board or | xNone | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Madeleine Burns |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | Imber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|---|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 Participation on a Data Safety Monitoring Board or | xNone | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Nicola Young |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|---|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 Participation on a Data Safety Monitoring Board or | xNone | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Yinay Mahajan |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|---|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 Participation on a Data Safety Monitoring Board or | xNone | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Soroush Hajizadeh |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|--|---------|--|
| | | | |
| | | | |
| | Payment or honoraria for | x _None | |
| | lectures, presentations, speakers bureaus, manuscript writing or | | |
| | | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Support for attending | xNone | |
| , | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 9 | Participation on a Data | x None | |
| 5 | Safety Monitoring Board or Advisory Board | | |
| | | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | xNone | |
| | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|-----------------------|---|
| Your Name: | Xcanda I. Herrera Lopez |
| Manuscript Tit | le: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | mber (if known): 149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone |
|----|--|--------|
| | | |
| 5 | 5 Payment or honoraria for lectures, presentations, | x_None |
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | xNone |
| | | |
| | | |
| 8 | Patents planned, issued or pending | xNone |
| | Penning | |
| 9 | Participation on a Data | xNone |
| | Safety Monitoring Board or Advisory Board | |
| 10 | Leadership or fiduciary role | xNone |
| | in other board, society, committee or advocacy | |
| 11 | group, paid or unpaid Stock or stock options | x None |
| 11 | Stock of stock options | |
| | | |
| 12 | Receipt of equipment, materials, drugs, medical | xNone |
| | writing, gifts or other services | |
| 13 | Other financial or non- financial interests | xNone |
| | | |

| Date:4 | l/26/2021 |
|------------------|---|
| Your Name: | Johannes Kreuzer |
| Manuscript Title | e: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrier | leading to SARS-CoV-2 antigenemia |
| Manuscript nun | nber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Robert Morris |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Enid Martinez |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Issac Han |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Kettner Griswold |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Nick Barry |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | Imber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | David Thompson |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | George Church |
| Manuscript Tit | le: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | mber (if known):149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Andrea Edlow |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|---|
| Your Name: | Wilhelm Haas |
| Manuscript Tit | tle: Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | Imber (if known): 149633-JCI-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Shiv PallaiShiv Pallai |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known <u>):149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------|--|
| Your Name: | Moshe Arditi |
| Manuscript Tit | tle: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| mucosal barrie | er leading to SARS-CoV-2 antigenemia |
| Manuscript nu | umber (if known <u>): 149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | x_None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Current for attending | v Nono | |
| / | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| 0 | Deuticiantica en e Dete | . News | |
| 9 | Participation on a Data Safety Monitoring Board or | xNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | x None | |
| | Stock of Stock Options | | |
| | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | x None | |
| 10 | financial interests | | |
| | | | |

| Date: | _4/26/2021 |
|----------------------|---|
| Your Name: | Galit Alter |
| Manuscript Ti | le: <u>Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut</u> |
| <u>mucosal barri</u> | er leading to SARS-CoV-2 antigenemia |
| Manuscript n | mber (if known): <u>149633-JCI-CMED-RV-2</u> |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | xNone | |
|----|--|--------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x_None | |
| 6 | Payment for expert testimony | xNone | |
| 7 | Support for attending meetings and/or travel | xNone | |
| 8 | Patents planned, issued or pending | xNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone | |
| 11 | Stock or stock options | xNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone | |
| 13 | Other financial or non- financial interests | xNone | |

| Date: | April 26, 2021 |
|-----------------|---|
| Your Name: | David R. Walt |
| Manuscript Tit | le:Multisystem Inflammatory Syndrome in Children is driven by zonulin-dependent loss of gut mucosal |
| barrier leading | to SARS-CoV-2 antigenemia |
| Manuscript nu | mber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | Chleck Foundation | |
| T | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Barbara and Amos Hostetter | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|--------------------------------|--|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | Patent Disclosure submitted | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | Quanterix Corporation | David Walt is a Board Director of Quanterix, which manufactures instruments and reagents used in this work. All instruments and reagents were purchased through normal commercial routes at typical academic pricing |
| 11 | Stock or stock options | Quanterix Corporation | David Walt holds stock equity in Quanterix, which manufactures instruments and reagents used in this work. All instruments and reagents were purchased through normal commercial routes at typical academic pricing |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |

| Date:April 26, 2021 | | |
|-------------------------------|--|--|
| Your Name:Alessio Fasano_ | | |
| Manuscript Title: | | |
| Manuscript number (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | 1 | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
|----|--|-------------------|---|
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |
| 11 | Stock or stock options | Alba Therapeutics | This company is focused on treatment of celiac disease using the same zonulin inhibitor use for some data presented in this paper. Beside stock options, no payments have been made for the past 36 months |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |